Benzinga·2025-11-04 14:53Market Overview - U.S. stocks traded lower, with the Dow Jones index falling more than 400 points, down 0.91% to 46,906.05, NASDAQ down 1.59% to 23,456.33, and S&P 500 down 1.17% to 6,772.04 [1] - Consumer staples shares increased by 0.5%, while information technology stocks decreased by 1.8% [1] Pfizer Inc. Performance - Pfizer reported better-than-expected third-quarter earnings of 87 cents, compared to $1.06 a year ago, surpassing the consensus estimate of 63 cents [2] - Third-quarter sales fell 6% year-over-year to $16.65 billion, slightly above the consensus of $16.59 billion, reflecting an operational decline of 7% [2] - Pfizer raised its fiscal 2025 adjusted earnings guidance from $2.90-$3.10 per share to $3.00-$3.15, compared to the consensus of $3.04 [3] Commodity Market - Oil prices decreased by 1.2% to $60.34, gold fell by 1.8% to $3,943.90, silver dropped 2.6% to $46.780, and copper also fell 2.6% to $4.9355 [6] European Market Performance - European shares were lower, with the eurozone's STOXX 600 declining 0.7%, Spain's IBEX 35 down 0.5%, London's FTSE 100 down 0.4%, Germany's DAX 40 down 1.2%, and France's CAC 40 down 0.9% [7] Asian Market Performance - Asian markets closed lower, with Japan's Nikkei 225 down 1.74%, Hong Kong's Hang Seng down 0.79%, China's Shanghai Composite down 0.41%, and India's BSE Sensex down 0.62% [8] Notable Stock Movements - Evoke Pharma shares surged 135% to $10.74 after announcing an acquisition agreement with QOL Medical [9] - Denny's Corporation shares rose 50% to $6.16 following an acquisition announcement valued at approximately $620 million [9] - Prelude Therapeutics shares dropped 56% to $1.7601 after signing an acquisition agreement with Incyte [9] - JELD-WEN Holding shares fell 38% to $2.61 after reporting worse-than-expected third-quarter results and cutting FY25 guidance [9]